MacroGenics, Inc.
MGNXMacroGenics, Inc. in brief
MacroGenics, Inc. is a listed company in the Biotechnology industry, based in Rockville, Maryland, USA. It was founded in 2000. Its market value was $238 M on 13 October 2026, which makes it the 15,646th largest listed company in the world and the 3,049th largest in the USA on this site. In the year to December 2025 it had sales of $150 M and a net loss of $75 M. It employs about 427 people and Eric Blasius Risser is its chief executive. Its largest product and service lines by sales in 2025 were Collaborative and other agreements (58%), Contract manufacturing (35%) and Royalty revenue (6%). Its shares trade under the symbol MGNX (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About MacroGenics, Inc.
MacroGenics is a Clinical Stage Biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody based therapeutics for the treatment of cancer. The company annual revenue is 64 million USD and 307 employees as on 2019. The headquarters is in USA.
MacroGenics, Inc. timeline
- 2000
- 🏁· approximateFounded
- 2003
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2013
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 11 October 2013; shares registered for exchange trading on 7 October 2013.
- 2022
- 💰Record revenue of $152 millionFY2022, the highest of the 8 years on record.
Events of MacroGenics, Inc. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #2,448 (Jan 2020) · #1,975 (Jan 2021) · #2,633 (Jan 2022) · #2,966 (Dec 2022) · #3,263 (Jul 2023) · #2,368 (Jan 2024) · #1,832 (Mar 2026) · #2,942 (Aug 2026) · #3,035 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 1.6×
- Price / book
- 4.3×
- Free cash flow yield
- -34.9%
- Net margin (TTM)
- -34.6%
- Operating margin
- -48.7%
- Return on equity
- -92.6%
- Liabilities / assets
- 78.4%
- Revenue growth
- -0.3%
- R&D / revenue
- 98.4%
- Revenue per employee
- $350 K
- Profit per employee
- $-175 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $150M | -0.3% | $-73M | $-75M | -49.9% |
| Dec 2024 | $150M | +155.3% | $-111M | $-67M | -44.7% |
| Dec 2023 | $59M | -61.3% | $-168M | $-9M | -15.4% |
| Dec 2022 | $152M | +96.2% | $-121M | $-120M | -78.8% |
| Dec 2021 | $77M | -26.2% | $-203M | $-202M | -261.0% |
| Dec 2020 | $105M | +63.4% | $-131M | $-130M | -123.7% |
| Dec 2019 | $64M | +6.8% | $-177M | $-152M | -236.5% |
| Dec 2018 | $60M | — | $-171M | $-171M | -285.2% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-81M | $2M | $-83M | $-1.18 | — |
| Dec 2024 | $-68M | $4M | $-72M | $-1.07 | — |
| Dec 2023 | $-78M | $2M | $-80M | $-0.15 | — |
| Dec 2022 | $-87M | $4M | $-91M | $-1.95 | — |
| Dec 2021 | $-144M | $6M | $-150M | $-3.37 | — |
| Dec 2020 | $-112M | $6M | $-118M | $-2.47 | — |
| Dec 2019 | $-134M | $4M | $-139M | — | — |
| Dec 2018 | $-153M | $25M | $-178M | — | — |
Quarterly results
Latest quarter to Sep 2026: revenue $19M (-64.8% on a year earlier), net income $-20M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 20268-KCurrent reportResults of operations
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Nov 3, 20268-KCurrent reportDirectors or officers changed · Regulation FD disclosure
- Oct 23, 20268-KCurrent reportOther events
- Sep 3, 20268-K/ACurrent report (amended)
- Aug 14, 202610-QQuarterly report · period to Jun 2026
- Aug 13, 20268-KCurrent reportResults of operations
- Jul 23, 20268-KCurrent reportOther events
- Jul 8, 20268-KCurrent reportDirectors or officers changed
- Jul 7, 20268-KCurrent reportAcquisition or disposal completed · Regulation FD disclosure
- May 20, 20268-KCurrent reportShareholder vote
- May 13, 20268-KCurrent reportResults of operations
Official filings of MacroGenics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $150 M
- Operating income
- $-73 M
- Net income
- $-75 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $257 M
- Total liabilities
- $201 M
- Total equity
- $56 M
As of December-2025
Top 100 institutional investors in MacroGenics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 6,149,936 | +1,470,707 (+31.43%) | 9.62% | $24 M | Nov 13, 2026 |
| 2 | Armistice Capital, LLC | 6,000,000 | +993,248 (+19.84%) | 9.39% | $23 M | Nov 16, 2026 |
| 3 | Vanguard Capital Management LLC | 2,679,146 | +23,136 (+0.87%) | 4.19% | $10 M | Nov 13, 2026 |
| 4 | Acadian Asset Management LLC | 2,542,431 | -212 (-0.01%) | 3.98% | $10 M | Nov 9, 2026 |
| 5 | Two Sigma Investments, LP | 2,381,144 | -84,555 (-3.43%) | 3.73% | $9 M | Nov 16, 2026 |
| 6 | Renaissance Technologies LLC | 2,179,430 | -453,320 (-17.22%) | 3.41% | $8 M | Nov 12, 2026 |
| 7 | Mackenzie Financial Corp | 2,013,592 | +370,966 (+22.58%) | 3.15% | $8 M | Nov 2, 2026 |
| 8 | Vanguard Portfolio Management LLC | 1,993,180 | +172,949 (+9.50%) | 3.12% | $8 M | Nov 13, 2026 |
| 9 | Ra Capital Management, L.P. | 1,864,176 | 0 (0.00%) | 2.92% | $7 M | Nov 16, 2026 |
| 10 | Geode Capital Management, LLC | 1,752,610 | +176,061 (+11.17%) | 2.74% | $7 M | Nov 6, 2026 |
| 11 | Marshall Wace, LLP | 1,343,462 | -272,758 (-16.88%) | 2.10% | $5 M | Nov 13, 2026 |
| 12 | Wasatch Advisors LP | 1,260,901 | -757,980 (-37.54%) | 1.97% | $5 M | Oct 13, 2026 |
| 13 | ADAR1 Capital Management, LLC | 1,234,595 | +1,104,773 (+850.99%) | 1.93% | $5 M | Nov 16, 2026 |
| 14 | Millennium Management LLC | 1,197,594 | -1,176,702 (-49.56%) | 1.87% | $5 M | Nov 16, 2026 |
| 15 | State Street Corp | 1,167,355 | +303,692 (+35.16%) | 1.83% | $5 M | Nov 12, 2026 |
| 16 | Connor, Clark & Lunn Investment Management Ltd. | 1,078,571 | +78,159 (+7.81%) | 1.69% | $4 M | Nov 10, 2026 |
| 17 | D. E. Shaw & Co., Inc. | 992,081 | -70,910 (-6.67%) | 1.55% | $4 M | Nov 16, 2026 |
| 18 | Affinity Asset Advisors, LLC | 953,979 | -262,627 (-21.59%) | 1.49% | $4 M | Nov 13, 2026 |
| 19 | Bank Of America Corp /de/ | 892,453 | -1,595,799 (-64.13%) | 1.40% | $3 M | Nov 16, 2026 |
| 20 | Jacobs Levy Equity Management, Inc | 776,956 | -225,318 (-22.48%) | 1.22% | $3 M | Nov 16, 2026 |
| 21 | Pinnacle Associates LTD | 647,713 | +393,412 (+154.70%) | 1.01% | $3 M | Oct 20, 2026 |
| 22 | Citadel Advisors LLC | 585,493 | +405,660 (+225.58%) | 0.92% | $2 M | Nov 16, 2026 |
| 23 | Northern Trust Corp | 523,519 | +7,390 (+1.43%) | 0.82% | $2 M | Nov 16, 2026 |
| 24 | Goldman Sachs Group Inc | 472,936 | -85,065 (-15.24%) | 0.74% | $2 M | Nov 16, 2026 |
| 25 | Vanguard Fiduciary Trust Co | 448,747 | +28,641 (+6.82%) | 0.70% | $2 M | Nov 13, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Nomura Asset Management International Inc. | 420,000 | 0 (0.00%) | 0.66% | $2 M | Nov 16, 2026 |
| 27 | FMR LLC | 419,014 | +335,396 (+401.11%) | 0.66% | $2 M | Nov 10, 2026 |
| 28 | Diadema Partners LP | 262,059 | -112,344 (-30.01%) | 0.41% | $1 M | Nov 16, 2026 |
| 29 | Panagora Asset Management Inc | 250,154 | 0 (0.00%) | 0.39% | $1 M | Nov 12, 2026 |
| 30 | Man Group plc | 237,468 | +49,279 (+26.19%) | 0.37% | $1 M | Nov 16, 2026 |
| 31 | Nuveen, LLC | 194,534 | +62,781 (+47.65%) | 0.30% | $1 M | Nov 10, 2026 |
| 32 | Charles Schwab Investment Management Inc | 192,639 | +4 (0.00%) | 0.30% | $1 M | Nov 16, 2026 |
| 33 | Strs Ohio | 178,400 | +35,900 (+25.19%) | 0.28% | $1 M | Oct 30, 2026 |
| 34 | LPL Financial LLC | 167,763 | -2,500 (-1.47%) | 0.26% | $1 M | Nov 6, 2026 |
| 35 | XTX Topco Ltd | 148,605 | +72,546 (+95.38%) | 0.23% | $1 M | Nov 16, 2026 |
| 36 | Russell Investments Group, Ltd. | 144,296 | +81,983 (+131.57%) | 0.23% | $1 M | Nov 6, 2026 |
| 37 | SEI Investments Co | 137,714 | -26,990 (-16.39%) | 0.22% | $1 M | Nov 10, 2026 |
| 38 | Bank of New York Mellon Corp | 135,089 | -468 (-0.35%) | 0.21% | $1 M | Nov 5, 2026 |
| 39 | Informed Momentum Co LLC | 124,033 | -47,672 (-27.76%) | 0.19% | $0 M | Nov 16, 2026 |
| 40 | Morgan Stanley | 118,713 | +25,925 (+27.94%) | 0.19% | $0 M | Nov 13, 2026 |
| 41 | Jump Financial, LLC | 109,800 | New | 0.17% | $0 M | Nov 13, 2026 |
| 42 | Amundi | 103,359 | -77,886 (-42.97%) | 0.16% | $0 M | Nov 6, 2026 |
| 43 | Point72 Asset Management, L.P. | 100,870 | New | 0.16% | $0 M | Nov 16, 2026 |
| 44 | Tudor Investment Corp Et Al | 90,676 | +74,327 (+454.63%) | 0.14% | $0 M | Nov 16, 2026 |
| 45 | Invesco Ltd. | 83,901 | -19,084 (-18.53%) | 0.13% | $0 M | Nov 12, 2026 |
| 46 | Alps Advisors Inc | 83,789 | +19,281 (+29.89%) | 0.13% | $0 M | Nov 3, 2026 |
| 47 | UBS Group AG | 82,209 | +40,374 (+96.51%) | 0.13% | $0 M | Nov 10, 2026 |
| 48 | Susquehanna Portfolio Strategies, LLC | 82,121 | -14,565 (-15.06%) | 0.13% | $0 M | Nov 16, 2026 |
| 49 | Caption Management, LLC | 77,715 | New | 0.12% | $0 M | Nov 16, 2026 |
| 50 | Ikarian Capital, LLC | 74,893 | 0 (0.00%) | 0.12% | $0 M | Nov 16, 2026 |
| 51 | Bridgeway Capital Management, LLC | 72,276 | -1,224 (-1.67%) | 0.11% | $0 M | Nov 16, 2026 |
| 52 | Empowered Funds, LLC | 72,276 | New | 0.11% | $0 M | Nov 13, 2026 |
| 53 | Rhumbline Advisers | 71,501 | +3,581 (+5.27%) | 0.11% | $0 M | Nov 10, 2026 |
| 54 | Vanguard Global Advisers, LLC | 68,506 | +45,686 (+200.20%) | 0.11% | $0 M | Nov 13, 2026 |
| 55 | Persistent Asset Partners Ltd | 66,733 | -28,638 (-30.03%) | 0.10% | $0 M | Nov 13, 2026 |
| 56 | Franklin Templeton Inc | 65,866 | -238 (-0.36%) | 0.10% | $0 M | Nov 12, 2026 |
| 57 | Dimensional Fund Advisors LP | 62,356 | -316,979 (-83.56%) | 0.10% | $0 M | Nov 4, 2026 |
| 58 | Barclays PLC | 61,312 | +11,482 (+23.04%) | 0.10% | $0 M | Nov 6, 2026 |
| 59 | Squarepoint Ops LLC | 60,654 | -56,724 (-48.33%) | 0.09% | $0 M | Nov 9, 2026 |
| 60 | Velan Capital Investment Management LP | 60,000 | 0 (0.00%) | 0.09% | $0 M | Nov 16, 2026 |
| 61 | Graham Capital Management, L.P. | 55,334 | +7,878 (+16.60%) | 0.09% | $0 M | Nov 16, 2026 |
| 62 | AQR Capital Management LLC | 55,015 | New | 0.09% | $0 M | Nov 16, 2026 |
| 63 | Deutsche Bank AG\ | 54,600 | -7,731 (-12.40%) | 0.09% | $0 M | Nov 6, 2026 |
| 64 | Price T Rowe Associates Inc /MD/ | 51,560 | 0 (0.00%) | 0.08% | $0 M | Nov 16, 2026 |
| 65 | Los Angeles Capital Management LLC | 49,589 | New | 0.08% | $0 M | Nov 12, 2026 |
| 66 | Employees Retirement System of Texas | 46,565 | New | 0.07% | $0 M | Nov 10, 2026 |
| 67 | Quadrature Capital Ltd | 45,941 | New | 0.07% | $0 M | Nov 13, 2026 |
| 68 | AlphaCore Capital LLC | 38,590 | +840 (+2.23%) | 0.06% | $0 M | Nov 4, 2026 |
| 69 | Spark Investment Management LLC | 38,200 | +21,000 (+122.09%) | 0.06% | $0 M | Nov 13, 2026 |
| 70 | DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | 36,467 | 0 (0.00%) | 0.06% | $0 M | Nov 16, 2026 |
| 71 | Pathstone Holdings, LLC | 32,070 | New | 0.05% | $0 M | Nov 13, 2026 |
| 72 | Susquehanna International Group, LLP | 32,065 | -21,554 (-40.20%) | 0.05% | $0 M | Nov 16, 2026 |
| 73 | Jpmorgan Chase & Co | 31,395 | +5,024 (+19.05%) | 0.05% | $0 M | Nov 12, 2026 |
| 74 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 30,341 | +1,541 (+5.35%) | 0.05% | $0 M | Nov 16, 2026 |
| 75 | Corient Private Wealth LP | 30,000 | 0 (0.00%) | 0.05% | $0 M | Nov 16, 2026 |
| 76 | Achmea Investment Management B.V. | 29,700 | New | 0.05% | $0 M | Oct 30, 2026 |
| 77 | MetLife Investment Management, LLC | 29,099 | -8,245 (-22.08%) | 0.05% | $0 M | Nov 16, 2026 |
| 78 | Lantern Wealth Advisors, LLC | 26,700 | +4,000 (+17.62%) | 0.04% | $0 M | Oct 22, 2026 |
| 79 | Cresset Asset Management, LLC | 25,827 | -1 (0.00%) | 0.04% | $0 M | Nov 16, 2026 |
| 80 | XML Financial, LLC | 24,836 | 0 (0.00%) | 0.04% | $0 M | Oct 29, 2026 |
| 81 | Prelude Capital Management, LLC | 22,705 | -3,595 (-13.67%) | 0.04% | $0 M | Nov 16, 2026 |
| 82 | EntryPoint Capital, LLC | 22,640 | New | 0.04% | $0 M | Nov 13, 2026 |
| 83 | Wells Fargo & Company/mn | 20,693 | -38,993 (-65.33%) | 0.03% | $0 M | Nov 16, 2026 |
| 84 | Aigen Investment Management, LP | 20,488 | New | 0.03% | $0 M | Nov 16, 2026 |
| 85 | Susquehanna Fundamental Investments, LLC | 19,826 | -10,075 (-33.69%) | 0.03% | $0 M | Nov 16, 2026 |
| 86 | WINTON GROUP Ltd | 19,100 | New | 0.03% | $0 M | Nov 12, 2026 |
| 87 | Police & Firemen's Retirement System of New Jersey | 18,525 | 0 (0.00%) | 0.03% | $0 M | Nov 9, 2026 |
| 88 | Boothbay Fund Management, LLC | 18,334 | 0 (0.00%) | 0.03% | $0 M | Nov 16, 2026 |
| 89 | Stifel Financial Corp | 17,588 | +3,087 (+21.29%) | 0.03% | $0 M | Nov 12, 2026 |
| 90 | Manufacturers Life Insurance Company, The | 17,324 | -357 (-2.02%) | 0.03% | $0 M | Nov 13, 2026 |
| 91 | Jane Street Group, LLC | 17,234 | -66,628 (-79.45%) | 0.03% | $0 M | Nov 12, 2026 |
| 92 | BNP Paribas Financial Markets | 16,285 | -8,032 (-33.03%) | 0.03% | $0 M | Nov 12, 2026 |
| 93 | Alliancebernstein L.P. | 15,780 | 0 (0.00%) | 0.02% | $0 M | Nov 16, 2026 |
| 94 | Vanguard Personalized Indexing Management, LLC | 15,706 | +818 (+5.49%) | 0.02% | $0 M | Nov 16, 2026 |
| 95 | Voya Investment Management LLC | 15,263 | +3,018 (+24.65%) | 0.02% | $0 M | Nov 10, 2026 |
| 96 | Sanders Morris Harris LLC | 12,345 | New | 0.02% | $0 M | Oct 14, 2026 |
| 97 | New York State Common Retirement Fund | 11,700 | 0 (0.00%) | 0.02% | $0 M | Nov 17, 2026 |
| 98 | Prudential Financial Inc | 10,075 | -17,700 (-63.73%) | 0.02% | $0 M | Nov 16, 2026 |
| 99 | Scotia Capital Inc. | 10,000 | New | 0.02% | $0 M | Nov 10, 2026 |
| 100 | Simplex Trading, LLC | 7,593 | -31,228 (-80.44%) | 0.01% | $0 M | Nov 4, 2026 |
Mutual funds holding MacroGenics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 1.93 M | $9 M | 3.0% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 1.56 M | $7 M | 2.4% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Wasatch Ultra Growth FundWasatch Advisors LP | 1.12 M | $5 M | 1.7% | 1.1% | −22% | Jun 30, 2026 |
| 🇺🇸 Wasatch Micro Cap FundWasatch Advisors LP | 771,218 | $4 M | 1.2% | 0.53% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 649,399 | $3 M | 1.0% | <0.01% | −0.4% | Jun 30, 2026 |
| 🇺🇸 Vanguard Strategic Small-Cap Equity FundThe Vanguard Group, Inc. | 551,029 | $3 M | 0.86% | 0.08% | +26% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 683,332 | $3 M | 1.1% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 513,042 | $2 M | 0.80% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Small Company Growth PortfolioThe Vanguard Group, Inc. | 437,607 | $2 M | 0.68% | 0.12% | no change | Jun 30, 2026 |
| 🇺🇸 Nomura Healthcare FundDelaware Management Company | 420,000 | $2 M | 0.66% | 0.26% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Explorer FundThe Vanguard Group, Inc. | 421,515 | $2 M | 0.66% | <0.01% | +137% | Jul 31, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 303,029 | $1 M | 0.47% | <0.01% | +62% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 211,153 | $1 M | 0.33% | 0.06% | +43% | Jun 30, 2026 |
| 🇺🇸 Fidelity SAI Small-Mid Cap Momentum Index FundFidelity Management & Research Company LLC | 177,801 | $1 M | 0.28% | 0.02% | new | Jul 31, 2026 |
| 🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc. | 146,320 | $1 M | 0.23% | <0.01% | −5.6% | May 31, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 152,584 | $1 M | 0.24% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 117,414 | $1 M | 0.18% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 111,316 | $0 M | 0.17% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 89,040 | $0 M | 0.14% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 73,500 | $0 M | 0.12% | 0.23% | no change | Jun 30, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 67,454 | $0 M | 0.11% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 83,633 | $0 M | 0.13% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC | 62,334 | $0 M | 0.10% | 0.04% | +56% | Jun 30, 2026 |
| 🇺🇸 PACE Small/Medium Co Growth Equity InvestmentsUBS Asset Management (Americas) LLC | 75,416 | $0 M | 0.12% | 0.11% | +118% | Jul 31, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 55,874 | $0 M | 0.09% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP | 65,703 | $0 M | 0.10% | <0.01% | −56% | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 51,056 | $0 M | 0.08% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 54,571 | $0 M | 0.09% | <0.01% | +115% | May 31, 2026 |
| 🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC | 48,120 | $0 M | 0.08% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 46,100 | $0 M | 0.07% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P. | 51,578 | $0 M | 0.08% | 0.02% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 42,073 | $0 M | 0.07% | <0.01% | +58% | May 31, 2026 |
| 🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC | 45,905 | $0 M | 0.07% | 0.02% | new | Jul 31, 2026 |
| 🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC | 43,475 | $0 M | 0.07% | <0.01% | −61% | Jul 31, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 32,408 | $0 M | 0.05% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 32,184 | $0 M | 0.05% | <0.01% | −16% | Jun 30, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 40,000 | $0 M | 0.06% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 31,781 | $0 M | 0.05% | <0.01% | −17% | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 29,153 | $0 M | 0.05% | <0.01% | +52% | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 30,003 | $0 M | 0.05% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 29,881 | $0 M | 0.05% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 21,600 | $0 M | 0.03% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 21,173 | $0 M | 0.03% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors | 20,334 | $0 M | 0.03% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Allspring Disciplined Small Cap FundAllspring Funds Management, LLC | 18,863 | $0 M | 0.03% | 0.05% | new | Jun 30, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 17,851 | $0 M | 0.03% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Small Cap Growth Insights FundGoldman Sachs Asset Management, L.P. | 21,557 | $0 M | 0.03% | 0.02% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 20,852 | $0 M | 0.03% | <0.01% | +3.3% | Jul 31, 2026 |
| 🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC | 15,251 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 14,018 | $0 M | 0.02% | 0.03% | +32% | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 13,911 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 13,923 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 13,600 | $0 M | 0.02% | <0.01% | −2.2% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 13,411 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP | 15,624 | $0 M | 0.02% | <0.01% | +35% | Jul 31, 2026 |
| 🇺🇸 AVIP BlackRock Advantage Small Cap Growth PortfolioCONSTELLATION INVESTMENTS INC | 12,187 | $0 M | 0.02% | 0.04% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 11,251 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 AST Small-Cap Equity PortfolioAST Investment Services, Inc. | 10,990 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 9,845 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 9,470 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 11,003 | $0 M | 0.02% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 8,463 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 8,203 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 7,890 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 7,890 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 7,755 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC | 8,766 | $0 M | 0.01% | <0.01% | +0.2% | Jul 31, 2026 |
| 🇺🇸 BlackRock Advantage Small Cap Growth FundBlackRock Funds | 6,392 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 7,355 | $0 M | 0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Strategic Advisers U.S. Total Stock FundStrategic Advisers LLC | 6,400 | $0 M | 0.01% | <0.01% | −87% | May 31, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 5,700 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 7,071 | $0 M | 0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc. | 5,496 | $0 M | <0.01% | <0.01% | −18% | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Variable Insurance Trust Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P. | 5,420 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 5,017 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 NVIT GS Small Cap Equity Insights FundNATIONWIDE FUND ADVISORS | 5,028 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC | 4,942 | $0 M | <0.01% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC | 4,500 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 4,490 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 5,536 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC | 4,217 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 BlackRock Advantage SMID Cap V.I. FundBlackRock Advisors, LLC | 4,126 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC | 4,178 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP | 3,958 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 JNL/DFA U.S. Core Equity FundJackson National Asset Management, LLC | 3,147 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 LVIP Dimensional U.S. Core Equity 1 FundLincoln Financial Investments Corporation | 2,941 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC | 2,915 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 LVIP Dimensional U.S. Core Equity 2 FundLincoln Financial Investments Corporation | 2,522 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 2,179 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 1,586 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC | 1,522 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 1,871 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 AZL DFA U.S. Core Equity FundAllianz Investment Management LLC | 1,449 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC | 1,433 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 1,282 | $0 M | <0.01% | <0.01% | −16% | Jun 30, 2026 |
| 🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC | 869 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP | 900 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC | 354 | $0 M | <0.01% | <0.01% | +6.0% | Jul 31, 2026 |
| 🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC | 186 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 99 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at MacroGenics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Ezio BonviniSr VP, Research & CSO | Option exercise | +8,000 | $2.600 | $21 K | 193,799 | Form 4 |
| filed | Jeffrey Stuart PetersSenior VP, GC, and Secretary | Sell10b5-1 plan | -31,105 | $4.150 | $129 K | 0 | Form 4 |
| filed | Ezio BonviniSr VP, Research & CSO | Option exercise | +40,000 | $2.600 | $104 K | 185,799 | Form 4 |
| filed | William K. HeidenDirector | Option exercise | +3,750 | — | — | 114,750 | Form 4 |
| filed | Edward HurwitzDirector | Option exercise | +3,750 | — | — | 47,824 | Form 4 |
| filed | Margaret LiuDirector | Option exercise | +3,750 | — | — | 14,750 | Form 4 |
| filed | Scott Thomas JacksonDirector | Option exercise | +3,750 | — | — | 14,750 | Form 4 |
| filed | Meenu ChhabraDirector | Option exercise | +3,750 | — | — | 14,750 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: MacroGenics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2026-05-11 20:25 UTC, code T3, resumed 21:45 UTC
Fails to deliver
- : 172 shares at $3.72
- : 149 shares at $3.55
- : 34 shares at $3.80
- : 20,558 shares at $4.14
- : 256 shares at $3.97
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
MacroGenics, Inc. scorecard#
Passes 6 of the 20 checks that could be worked out: strongest in profitability (2 of 5), weakest in growth (1 of 6). Fiscal year 2025; market cap of Oct 13, 2026.
Valuation1 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median4.3×Price to book 4.3× against Biotechnology's median of 2.9×.
- ✓Price to sales below its peers' median1.6×Price to sales 1.6× against Biotechnology's median of 8.7×.
- ✗Free cash flow yield above 5%-34.9%Free cash flow is -34.9% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 6
- ✗Revenue grew in the newest year-0.3%Revenue down 0.3% in fiscal 2025.
- ✗Revenue up more than 5% a year over three years-0.5%-0.5% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median-0.5%-0.5% a year against Biotechnology's median of 12.9% (181 companies).
- ✗Earnings per share grew in the newest year-1.18 vs -1.07Diluted EPS -1.18 in fiscal 2025 against -1.07 the year before (report's currency).
- ✓Net income higher than five years earlier-$75 M-$75 M in fiscal 2025 against -$130 M in 2020.
- ✗Revenue rose in at least four of the last five years2 of 5Revenue rose in 2 of the five years to fiscal 2025.
Profitability2 of 5
- ✗Profitable in the newest year-$75 MNet income -$75 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✓Operating margin above its peers' median-48.7%-48.7% against Biotechnology's median of -60.5% (243 companies).
- ✗Return on equity above 15%-86.9%-86.9% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-48.7%-48.7% in fiscal 2025 against -79.9% in 2022.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities5.1×Current ratio 5.10 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-5.60Z-score -5.60 (distress zone) for fiscal 2025.
Shareholder returns1 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✓Share count up no more than 2% in a year0.8%Diluted shares up 0.8% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from MacroGenics, Inc.'s statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -48.7% | -60.5% | |
| Net margin | -49.9% | -68.9% | |
| Return on equity | -86.9% | -61.0% | |
| Revenue growth, 3 years a year | -0.5% | 12.9% | |
| Revenue growth | -0.3% | 15.8% | |
| Free cash flow margin | -55.5% | -61.5% |
3of 8on the Piotroski tests of financial strength
- Revenue fell 0.3% against the year before.
- Net loss of $75 million, the 13th loss-making year in a row.
- Free cash flow was negative: -$83 million.
MacroGenics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 150−0.3%100% | 150+155%100% | 59−61.3%100% | 152+96.2%100% | 77−26.2%100% | 105+63.4%100% | 64+6.8%100% | 60−61.9%100% | 158+71.7%100% | 92—100% | |
| Cost of revenue | 0−100%0.0% | 0.8+36.8%0.6% | 0.6−81.5%1.1% | 3.4+26.4%2.2% | 2.7—3.4% | 0—0.0% | 0—0.0% | — | — | — | |
| Research and development | 147−16.9%98.4% | 177+6.4%118% | 167−19.5%284% | 207−3.5%136% | 215+11.1%277% | 193−1.1%184% | 195+2.3%304% | 191+29.6%317% | 147+20.6%93.3% | 122—133% | |
| General and administrative | 39−44.9%26.2% | 71+36.1%47.4% | 52−11.5%88.8% | 59−6.5%38.8% | 63+47.4%81.4% | 43−7.2%40.8% | 46+13.7%71.8% | 41+24.0%67.4% | 33+9.5%20.7% | 30—32.5% | |
| Total costs and expenses | 222−14.7%149% | 261+14.8%174% | 227−17.0%386% | 273−2.5%180% | 280+18.8%362% | 236−2.2%225% | 241+4.3%376% | 231+28.6%385% | 180+18.4%114% | 152—165% | |
| Operating income | −73—−48.7% | −111—−73.7% | −168—−286% | −121—−79.9% | −203—−262% | −131—−125% | −177—−276% | −171—−285% | −22—−14.0% | −60—−65.3% | |
| Interest expense and finance costs | 8.5+663%5.7% | 1.1−22.0%0.7% | 1.4—2.4% | 0—0.0% | 0—0.0% | — | — | — | — | — | |
| Other non-operating income (expense) | 6.1−35.7%4.1% | 9.4−2.7%6.3% | 9.7+483%16.5% | 1.7+144%1.1% | 0.7−48.5%0.9% | 1.3−94.8%1.3% | 25—39.5% | −0.2−110%−0.4% | 2.5+66.2%1.6% | 1.5—1.6% | |
| Income before tax | −75—−50.4% | −66—−44.0% | −9.1—−15.4% | −120—−78.8% | — | — | — | — | — | — | |
| Income tax | −0.7−171%−0.4% | 0.9—0.6% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | |
| Net income attributable to shareholders | −75—−49.9% | −67—−44.7% | −9.1—−15.4% | −120—−78.8% | −202—−261% | −130—−124% | −152—−237% | −171—−285% | −20—−12.4% | −59—−63.7% | |
| Earnings per share, basic | -1.18—— | -1.07—— | -0.15—— | -1.95—— | -3.37—— | -2.47—— | — | — | -0.54—— | -1.69—— | |
| Earnings per share, diluted | -1.18—— | -1.07—— | -0.15—— | -1.95—— | -3.37—— | -2.47—— | — | — | -0.54—— | -1.69—— | |
| Shares, weighted average (basic) | 63+0.9%— | 63+1.1%— | 62+0.8%— | 61+2.5%— | 60+14.3%— | 52+9.1%— | 48—— | — | 36+4.1%— | 35—— | |
| Shares, weighted average (diluted) | 63+0.9%— | 63+1.1%— | 62+0.8%— | 61+2.5%— | 60+14.3%— | 52+9.1%— | 48+17.5%— | 41+13.4%— | 36+4.1%— | 35—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 57−68.7%22.3% | 183+81.1%69.9% | 101−7.3%33.8% | 109−11.8%38.8% | 123−31.8%36.8% | 181+43.2%47.8% | 126−42.5%40.5% | 220+4.0%66.3% | 212+152%56.6% | 84—27.0% | |
| Receivables | 0.4r13−90.1%0.2% | 4.3−58.4%1.6% | 10−81.6%3.5% | 56+441%20.0% | 10−55.0%3.1% | 23+81.1%6.1% | 13−56.9%4.1% | 30+117%8.9% | 14+394%3.6% | 2.8—0.9% | |
| Inventory | 7.9—3.1% | 0−100%0.0% | 1.2−15.9%0.4% | 1.5−66.9%0.5% | 4.4—1.3% | 0—0.0% | — | — | — | — | |
| Other current assets | 7.2r8.7−37.3%2.8% | 12+15.8%4.4% | 9.9−2.1%3.3% | 10−52.0%3.6% | 21+24.7%6.3% | 17—4.5% | — | — | — | — | |
| Current assets | 220+1.1%85.6% | 217−13.5%83.1% | 251+13.1%84.2% | 222−20.5%79.2% | 280−10.6%83.4% | 313+30.4%82.5% | 240−10.9%76.7% | 269−16.5%81.0% | 322+13.5%86.2% | 284—91.2% | |
| Property, plant and equipment | 2.1r13−88.4%0.8% | 18−17.2%6.9% | 22−26.1%7.3% | 30−21.5%10.5% | 38−10.8%11.2% | 42−12.4%11.1% | 48−15.0%15.4% | 57+13.5%17.1% | 50+178%13.4% | 18—5.8% | |
| Right-of-use (leased) assets | 22r23−11.1%8.5% | 25+2.8%9.4% | 24−12.8%8.0% | 27+64.5%9.7% | 17r17−13.9%5.0% | 19−4.5%5.1% | 20—6.5% | — | — | — | |
| Total assets | 257−1.8%100% | 262−12.3%100% | 298+6.4%100% | 280−16.3%100% | 335−11.5%100% | 379+21.2%100% | 313−5.9%100% | 332−11.2%100% | 374+20.1%100% | 311—100% | |
| Accounts payable | 3.3r4.8−35.0%1.3% | 5.0−22.2%1.9% | 6.4+31.5%2.2% | 4.9−68.4%1.7% | 16+93.0%4.6% | 8.0+86.4%2.1% | 4.3+7.6%1.4% | 4.0+63.4%1.2% | 2.5−38.6%0.7% | 4.0—1.3% | |
| Current liabilities | 43−22.4%16.8% | 56−1.0%21.2% | 56+15.4%18.8% | 49−34.8%17.3% | 75+47.2%22.2% | 51+12.2%13.4% | 45−24.6%14.5% | 60+20.5%18.0% | 50+82.2%13.3% | 27—8.8% | |
| Lease liabilities (non-current) | 31r32−6.1%11.9% | 33+8.0%12.5% | 30+0.3%10.1% | 30+44.8%10.7% | 21−17.7%6.2% | 25−8.3%6.7% | 28—8.8% | 0—0.0% | — | — | |
| Total liabilities | 201+38.2%78.4% | 146−0.1%55.6% | 146+5.3%48.9% | 138+44.8%49.4% | 96+15.4%28.5% | 83+1.2%21.9% | 82−8.3%26.2% | 89+19.6%26.9% | 75+75.6%20.0% | 43—13.7% | |
| Retained earnings | −1,244—−484% | −1,170—−447% | −1,103—−370% | −1,094—−390% | −974—−291% | −772—−204% | −642—−205% | −490—−148% | −312—−83.5% | −293—−94.0% | |
| Shareholders' equity | 56−52.1%21.6% | 116−24.0%44.4% | 153+7.5%51.1% | 142−40.7%50.6% | 240−19.0%71.5% | 296+28.3%78.1% | 231−5.0%73.8% | 243−18.8%73.1% | 299+11.3%80.0% | 269—86.3% | |
| Total equity | 56−52.1%21.6% | 116−24.0%44.4% | 153+7.5%51.1% | 142−40.7%50.6% | 240−19.0%71.5% | 296+28.3%78.1% | 231−5.0%73.8% | 243−18.8%73.1% | 299—80.0% | — | |
| Total liabilities and equity | 257−1.8%100% | 262−12.3%100% | 298+6.4%100% | 280−16.3%100% | 335−11.5%100% | 379+21.2%100% | 313−5.9%100% | 332−11.2%100% | 374+20.1%100% | 311—100% | |
| Shares outstanding | 63+0.8%— | 63+1.2%— | 62+0.6%— | 62+0.6%— | 61+9.0%— | 56+14.9%— | 49+15.6%— | 42+14.9%— | 37+5.7%— | 35—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 7.2−4.9%4.8% | 7.5−21.8%5.0% | 9.6−18.7%16.4% | 12+5.4%7.8% | 11−5.8%14.5% | 12−2.8%11.4% | 12r11+34.3%19.2% | 9.2r8.3+26.7%15.2% | 7.2−5.0%4.6% | 7.6—8.3% | |
| Share-based compensation | 14−51.5%9.6% | 29+60.2%19.6% | 18−10.1%31.3% | 20−11.6%13.5% | 23+11.8%29.9% | 21+5.6%19.7% | 20+18.5%30.5% | 17+12.0%27.5% | 15+21.2%9.3% | 12—13.2% | |
| Cash from operating activities | −81—−54.2% | −68—−45.6% | −78—−133% | −87—−57.2% | −144—−186% | −112—−107% | −134—−209% | −153−1164%−255% | 14—9.1% | −44—−47.5% | |
| Capital expenditure | −1.9—−1.3% | −3.7—−2.5% | −1.8—−3.0% | −3.6—−2.4% | −6.2—−8.0% | −5.9—−5.6% | −4.3—−6.7% | −25—−41.5% | −29—−18.6% | −11—−12.4% | |
| Cash from investing activities | −114−176%−76.3% | 149—99.6% | −80−213%−136% | 71—46.5% | −37—−47.3% | −7.8—−7.4% | −79−240%−124% | 57−27.3%94.2% | 78—49.4% | −70—−76.5% | |
| Shares issued | 0—0.0% | 0−100%0.0% | 0.6−43.2%1.0% | 1.1−99.1%0.7% | 118−30.9%152% | 170+43.7%163% | 119+14.9%185% | 103+202%172% | 34—21.7% | 0—0.0% | |
| Cash from financing activities | 70+7141%46.5% | 1.0−99.4%0.6% | 150+8963%256% | 1.7−98.6%1.1% | 123−29.6%159% | 174+45.3%166% | 120+14.3%187% | 105+197%175% | 35+1807%22.4% | 1.9—2.0% | |
| Change in cash | −126−253%−84.0% | 82—54.6% | −7.9—−13.5% | −15—−9.6% | −58−205%−74.5% | 55—52.1% | −94−1215%−146% | 8.4−93.4%14.0% | 128—80.9% | −112—−122% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 155+67.6%100% | 19−64.8%100% | 33+378%100% | 21+57.5%100% | 83r41*+327%100% | 53r73−52.1%100% | 6.9r22−36.4%100% | 13+44.9%100% | 19*+80.5%100% | 111—100% | 11—100% | 9.1—100% | 11*—100% | |
| Cost of revenue | — | — | — | — | 0*−100%0.0% | 0−100%0.0% | 0−100%0.0% | 0−100%0.0% | 0.2*+42.9%1.2% | 0.2—0.2% | 0.2—1.6% | 0.3—3.0% | 0.2*—1.5% | |
| Research and development | 138−9.0%89.3% | 31−6.4%164% | 39−4.9%118% | 35−11.9%168% | 34*−12.6%41.1% | 33−19.3%61.7% | 41−21.1%594% | 40−13.8%301% | 39*−17.9%201% | 41—36.6% | 52—479% | 46—506% | 47*—442% | |
| General and administrative | 35−39.0%22.7% | 8.4−15.6%44.8% | 7.9−15.0%24.1% | 9.7−9.4%46.7% | 9.2*−66.8%11.2% | 9.9−29.8%18.7% | 9.3−35.5%135% | 11−27.1%81.2% | 28*+121%144% | 14—12.7% | 14—134% | 15—162% | 13*—117% | |
| Total costs and expenses | 219−0.7%141% | 39−8.6%209% | 47−6.8%142% | 54−2.9%261% | 79r53*+9.7%95.9% | 43r54−24.6%80.4% | 50r59−27.4%729% | 56−11.2%423% | 72*+20.2%373% | 57—51.1% | 69—639% | 63—690% | 60*—560% | |
| Operating income | −64—−41.5% | −20−295%−109% | −14—−42.2% | −33—−161% | 3.4r−12*—4.1% | 10r19−80.8%19.6% | −43r−37—−629% | −43—−323% | −53*—−273% | 54—48.9% | −58—−539% | −54—−590% | −49*—−460% | |
| Interest expense and finance costs | — | 4.1+22.2%21.9% | 4.4+448%13.4% | 4.9+5273%23.5% | — | 3.3—6.3% | 0.8+13267%11.7% | 0.1−92.0%0.7% | — | 0—0.0% | 0.0—0.1% | 1.1—12.4% | 0*—0.0% | |
| Income before tax | — | −21−350%−115% | −70—−212% | — | 0.5r−15*—0.6% | 8.6r17−84.8%16.2% | −43r−36—−620% | — | −14*—−74.8% | 56—50.9% | −56—−516% | — | — | |
| Income tax | — | 0—0.0% | 0−100%0.0% | — | −0.8*−182%−0.9% | 0—0.0% | 0.1—1.5% | — | 0.9*—4.9% | 0—0.0% | 0—0.0% | — | — | |
| Income from continuing operations | — | −21−350%−115% | −70—−212% | — | — | 8.6—16.2% | −43—−622% | — | — | — | — | — | — | |
| Income from discontinued operations | — | 1.4−83.0%7.5% | 89+1279%272% | — | — | 8.2—15.6% | 6.5—94.1% | — | — | — | — | — | — | |
| Net income attributable to shareholders | −51—−33.2% | −20−219%−108% | 20—59.4% | −37—−177% | −14*—−17.1% | 17−70.1%31.7% | −36—−528% | −41—−311% | −15*—−79.7% | 56—50.9% | −56—−516% | −52—−573% | −46*—−430% | |
| Earnings per share, basic | — | -0.32−219%— | 0.31—— | -0.58—— | — | 0.27−70.0%— | -0.57—— | -0.65—— | — | 0.90—— | -0.89—— | -0.84—— | — | |
| Earnings per share, diluted | — | -0.32−219%— | 0.31—— | -0.58—— | — | 0.27−70.0%— | -0.57—— | -0.65—— | — | 0.90—— | -0.89—— | -0.84—— | — | |
| Shares, weighted average (basic) | 64+0.8%— | 64+0.8%— | 64+0.7%— | 63+0.8%— | — | 63+0.8%— | 63+0.8%— | 63+1.1%— | — | 63—— | 63—— | 62—— | — | |
| Shares, weighted average (diluted) | 64+0.7%— | 64+0.7%— | 64+0.7%— | 63+0.8%— | — | 63+0.7%— | 63+0.8%— | 63+1.1%— | — | 63—— | 63—— | 62—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 49—15.4% | 49−38.8%15.4% | 114−12.8%33.0% | 67−54.3%30.5% | 57−68.7%22.3% | 80−55.4%29.6% | 131+55.7%53.3% | 146+81.2%64.8% | 183+81.1%69.9% | 180—67.9% | 84—41.7% | 80—32.4% | 101—33.8% | |
| Receivables | 0.4—0.1% | 0.4−99.4%0.1% | 25+96.3%7.1% | 10−1.1%4.8% | 0.4r13−90.1%0.2% | 69+691%25.6% | 13+102%5.1% | 11+46.0%4.7% | 4.3−58.4%1.6% | 8.8—3.3% | 6.2—3.1% | 7.2—2.9% | 10—3.5% | |
| Inventory | — | — | — | 9.5+0.8%4.4% | 7.9—3.1% | 8.8+170%3.2% | 9.3+732%3.8% | 9.4+655%4.2% | 0−100%0.0% | 3.2—1.2% | 1.1—0.6% | 1.2—0.5% | 1.2—0.4% | |
| Other current assets | 5.5—1.7% | 5.5−28.8%1.7% | 4.2−36.7%1.2% | 8.4+4.9%3.8% | 7.2r8.7−37.3%2.8% | 7.7−21.6%2.8% | 6.7−28.3%2.7% | 8.0−19.2%3.6% | 12+15.8%4.4% | 9.8—3.7% | 9.3—4.6% | 9.9—4.0% | 9.9—3.3% | |
| Current assets | 295—92.6% | 295+27.1%92.6% | 322+57.0%93.1% | 183+0.2%83.8% | 220+1.1%85.6% | 232+4.5%85.7% | 205+30.6%83.5% | 182−10.1%81.1% | 217−13.5%83.1% | 222—84.0% | 157—78.0% | 203—81.6% | 251—84.2% | |
| Property, plant and equipment | 2.2—0.7% | 2.2−84.0%0.7% | 2.4−84.5%0.7% | 11−31.9%5.3% | 2.1r13−88.4%0.8% | 14−26.8%5.2% | 15−24.6%6.3% | 17−20.8%7.5% | 18−17.2%6.9% | 19—7.2% | 20—10.1% | 21—8.6% | 22—7.3% | |
| Right-of-use (leased) assets | 21—6.5% | 21−11.3%6.5% | 21−10.8%6.1% | 22−6.8%10.3% | 22r23−11.1%8.5% | 23+5.9%8.6% | 24+4.8%9.7% | 24+3.8%10.7% | 25+2.8%9.4% | 22—8.3% | 23—11.2% | 23—9.4% | 24—8.0% | |
| Total assets | 319—100% | 319+17.7%100% | 345+40.7%100% | 218−3.0%100% | 257−1.8%100% | 271+2.4%100% | 245+22.0%100% | 225−9.6%100% | 262−12.3%100% | 264—100% | 201—100% | 248—100% | 298—100% | |
| Accounts payable | 3.1—1.0% | 3.1−47.1%1.0% | 3.4−26.1%1.0% | 4.3−35.2%2.0% | 3.3r4.8−35.0%1.3% | 5.9−10.2%2.2% | 4.7−11.1%1.9% | 6.6−38.1%2.9% | 5.0−22.2%1.9% | 6.6—2.5% | 5.2—2.6% | 11—4.3% | 6.4—2.2% | |
| Current liabilities | 107—33.6% | 107+141%33.6% | 109+179%31.5% | 96+73.0%44.0% | 43−22.4%16.8% | 44−25.0%16.4% | 39−32.6%15.9% | 55−0.6%24.7% | 56−1.0%21.2% | 59—22.4% | 58—28.8% | 56—22.5% | 56—18.8% | |
| Lease liabilities (non-current) | 30—9.3% | 30−6.9%9.3% | 30−6.3%8.7% | 31−2.5%14.4% | 31r32−6.1%11.9% | 32+8.6%11.8% | 32+8.3%13.1% | 32+7.3%14.3% | 33+8.0%12.5% | 29—11.1% | 30—14.7% | 30—12.1% | 30—10.1% | |
| Total liabilities | 294—92.1% | 294+44.1%92.1% | 303+52.2%87.6% | 197+35.2%90.3% | 201+38.2%78.4% | 204+41.1%75.3% | 199+38.7%81.0% | 145+2.3%64.8% | 146−0.1%55.6% | 144—54.6% | 143—71.3% | 142—57.2% | 146—48.9% | |
| Retained earnings | −1,282—−402% | −1,282—−402% | −1,262—−365% | −1,281—−588% | −1,244—−484% | −1,230—−454% | −1,247—−508% | −1,211—−539% | −1,170—−447% | −1,154—−436% | −1,211—−602% | −1,155—−465% | −1,103—−370% | |
| Shareholders' equity | 25—7.9% | 25−62.5%7.9% | 43−8.0%12.4% | 21−73.2%9.7% | 56−52.1%21.6% | 67−44.2%24.7% | 47−19.4%19.0% | 79−25.5%35.2% | 116−24.0%44.4% | 120—45.4% | 58—28.7% | 106—42.8% | 153—51.1% | |
| Total equity | 25—7.9% | 25−62.5%7.9% | 43−8.0%12.4% | 21−73.2%9.7% | 56−52.1%21.6% | 67−44.2%24.7% | 47−19.4%19.0% | 79−25.5%35.2% | 116−24.0%44.4% | 120—45.4% | 58—28.7% | 106—42.8% | 153—51.1% | |
| Total liabilities and equity | 319—100% | 319+17.7%100% | 345+40.7%100% | 218−3.0%100% | 257−1.8%100% | 271+2.4%100% | 245+22.0%100% | 225−9.6%100% | 262−12.3%100% | 264—100% | 201—100% | 248—100% | 298—100% | |
| Shares outstanding | 64—— | 64+1.0%— | 64+0.7%— | 64+0.7%— | 63+0.8%— | 63+0.8%— | 63+0.8%— | 63+0.8%— | 63+1.2%— | 63—— | 63—— | 63—— | 62—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 4.3−42.8%2.8% | 0.2*−88.9%1.1% | 0.7*−62.9%2.2% | 1.7−4.7%8.1% | 1.7*−17.0%2.1% | 1.8*−2.5%3.4% | 1.9*+5.3%27.8% | 1.8−3.8%13.4% | 2.1*+8.1%10.6% | 1.8*—1.7% | 1.8*—16.8% | 1.8—20.2% | 1.9*—17.7% | |
| Share-based compensation | 9.3−59.2%6.0% | 2.1−42.0%11.0% | 2.0−46.5%6.0% | 2.6−39.7%12.7% | 2.7*−76.4%3.2% | 3.5−40.6%6.7% | 3.7−44.5%53.7% | 4.4−21.0%33.2% | 11*+158%58.2% | 6.0—5.4% | 6.7—61.6% | 5.6—61.0% | 4.4*—40.7% | |
| Cash from operating activities | −40—−25.7% | −6.3*—−33.9% | −41*—−124% | −36—−172% | 43*—52.1% | −30*−150%−57.0% | −47*—−684% | −47—−355% | −38*—−198% | 60*—54.3% | −44*—−412% | −46—−501% | −28*—−262% | |
| Capital expenditure | −1.5—−0.9% | −0.1*—−0.4% | −0.8*—−2.5% | −0.3—−1.7% | −0.2*—−0.3% | −0.4*—−0.8% | −0.7*—−10.4% | −0.5—−4.0% | −0.6*—−3.2% | −0.6*—−0.5% | −1.0*—−9.6% | −1.5—−16.0% | −0.6*—−5.8% | |
| Cash from investing activities | −52—−33.5% | −59*—−317% | 28*—85.2% | 45+358%218% | −66*−259%−79.9% | −20*−157%−38.4% | −38*−179%−548% | 9.9−60.1%75.1% | 41*+6.8%214% | 36*—32.2% | 47*—439% | 25—272% | 39*—362% | |
| Shares issued | — | — | — | — | — | — | — | — | 0*—0.0% | 0*—0.0% | 0*—0.0% | 0—0.0% | 0*—0.0% | |
| Cash from financing activities | 61−12.9%39.1% | 0.6*—3.2% | 60*−13.7%183% | −0.2—−1.0% | 0.1*−63.2%0.1% | 0*—0.0% | 70*+11058%1015% | −0.3−214%−2.1% | 0.2*−43.2%0.8% | −0.1*—−0.1% | 0.6*—5.8% | 0.2—2.7% | 0.3*—2.5% | |
| Change in cash | −31—−20.1% | −65*—−348% | 47*—144% | 9.3—44.8% | −23*−813%−27.7% | −51*−153%−95.4% | −15*−516%−217% | −37—−283% | 3.2*−70.9%16.6% | 96*—86.4% | 3.6*—33.1% | −21—−226% | 11*—103% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What MacroGenics, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Collaborative and other agreements$87 M58%-27%
- Contract manufacturing$53 M35%+303%
- Royalty revenue$10 M6.5%+1630%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Executive pay at MacroGenics, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Eric Blasius Risser | $2.1 M | $1.5 M | $1.2 M | $7 |
| 2024Eric Blasius Risser | $6.4 M | $1.8 M | $2.5 M | $14 |
| 2023Eric Blasius Risser | $3.7 M | $6.5 M | $1.7 M | $42 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at MacroGenics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Acquisition or sale completed 1 · Directors and officers 7 · Material agreement 3 · Shareholder vote 2 · Results announced 9
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Acquisition or sale completed | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Material agreement | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jan 2011 | $12 M | No. 1 | $10 to $50 million | 3 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at MacroGenics, Inc.#
1 labor condition applications certified in fiscal 2025 for 1 positions, at a median wage of $230 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Senior Director, ToxicologyNatural Sciences Managers | 1 | $230 K |
Where: Rockville, MD 1
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2025 | 1 | 1 | $230 K | 1 |
| FY2023 | 4 | 4 | $117 K | 4 |
| FY2022 | 1 | 1 | $69 K | 1 |
| FY2021 | 2 | 2 | $112 K | 2 |
| FY2020 | 3 | 3 | $99 K | 3 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as MacroGenics, Inc.
How MacroGenics, Inc. compares in Biotechnology
- Market cap$238 M · higher than 47% of 726
- Revenue$150 M · higher than 73% of 647
- Net margin-34.6% · higher than 55% of 408
- Revenue growth-0.3% · higher than 42% of 438
- Price / sales1.6× · lower than 88% of 339
- Price / book4.3× · lower than 36% of 534
- FCF yield-34.9% · higher than 32% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| MacroGenics, Inc.🇺🇸 | $238 M | — | -34.6% | -0.3% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 13, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As on 2021
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at MacroGenics, Inc.? Verify and update this profile — free
Show MacroGenics, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.